



Head of Bertarelli
Foundation Gene
Therapy Platform
Campus Biotech
Genève, CH

Education & Training

DOCTOR OF PHILOSOPHY

1995 - 2001
Gene Therapy
University of Lausanne - CH

POSTDOCTORAL FELLOW

2001-2003
EPFL,
Lausanne, Switzerland

ASSISTANT SCIENTIST

2003-2006
University of Wisconsin
USA

SENIOR SCIENTIST

2007 - Present
EPFL,
Lausanne, Switzerland

BERNARD

SCHNEIDER

Gene Therapy

Profile

Dr. Bernard Schneider is a prominent neuroscientist and a Research and Teaching Associate at the Brain Mind Institute of EPFL. He leads the Bertarelli Gene Therapy Platform, focusing on developing viral vectors for gene therapies targeting neurodegenerative diseases and sensory organ disorders, such as ALS, deafness, and blindness. With over 16 years of experience in neuroscience, Dr. Schneider has authored more than 100 publications and is a key figure in translational research.

Articles

- Long term peripheral AAV9-SMN gene therapy promotes survival in a mouse model of spinal muscular atrophy
- Stable isotope labeling and ultra-high-resolution NanoSIMS imaging reveal alpha-synuclein-induced changes in neuronal metabolism in vivo
- Recovery of walking after paralysis by regenerating characterized neurons to their natural target region



[linkedin.com/in/bernard-schneider-9894792](https://www.linkedin.com/in/bernard-schneider-9894792)



[Bertarelli Foundation Gene Therapy Platform](#)



bernard.schneider@epfl.ch